The incidence of inflammatory bowel disease (IBD) is rapidly rising throughout the world.
Although tremendous efforts have been made, limited therapeutics are available for IBD …

Background Biological therapy is currently widely used to treat IBD. Infliximab, adalimumab
and golimumab are currently licensed anti‐TNF therapies. Biosimilar anti‐TNF monoclonal …

Background We analysed incidence, predictors, histological features and specific treatment
options of anti-tumour necrosis factor α (TNF-α) antibody-induced psoriasiform skin lesions …

Psoriasis is a skin disease where various cytokines play a detrimental role, yet our
understanding of the disease is still limited. TNF is a validated drug target in psoriasis and …

Inflammatory bowel disease (IBD) is a disease that affects the intestinal tract via an
inflammatory process. Patients who suffer from IBD often have diseases that affect multiple …

Objective Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative
colitis (UC), shares clinical and immunological features with psoriasis. Genome-wide …

Aliment Pharmacol Ther 2011; 34: 1318–1327 Summary Background Anti‐tumour necrosis
factor (TNF) antibodies are used to treat both psoriasis and inflammatory bowel disease. The …

Background Tumor necrosis factor-α (TNF-α) inhibitors have been reported to induce new-
onset psoriasis. Objective To better define the demographic, clinical features, and treatment …

Tumor necrosis factor α (TNF-α)-targeted therapies have expanded the therapeutic options
for patients with inflammatory bowel disease (IBD), rheumatoid arthritis (RA), psoriasis, and …

Anti-TNF antibodies have acquired a prominent place in the management of IBD (including
Crohn's disease and ulcerative colitis), rheumatologic conditions (such as rheumatoid …